Scientific Publications
AML and ALL Classification and Metabolic Characteristics for Informing and Advancing Treatment
Cancers
Acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) remain significant challenges in haematological oncology. This comprehensive review examines the pathophysiology, classification, and risk stratification of these aggressive malignancies, emphasising their impact on treatment strategies and prognosis. We discuss current standard-of-care treatments, including chemotherapy regimens and targeted therapies, while addressing the associated adverse effects and hypersensitivity reactions. Delving into the metabolic characteristics and vulnerabilities of leukaemia cells, the review highlights the key differences between lymphoid and myeloid leukaemia. We explore how these metabolic insights can be utilized for therapeutic purposes, with a special focus given to asparaginase therapy and its potential for improvement in both ALL and AML treatment. The review conveys the importance of personalized medicine approaches based on individual metabolic profiles and the challenges posed by metabolic heterogeneity and plasticity in leukaemia cells. By integrating molecular and metabolic profiling, this review aims to inform and advance treatment strategies for acute leukaemia, potentially improving patient outcomes and quality of life.
Cancers
View Publication
